Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.
Will a TIGIT refocus see the stars finally align for the partners?
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?
Merck adds an overall survival benefit while Bristol sinks further.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.